Continue Reading Below
According to data fromS&P Global Market Intelligence, shares of the leading RNA interference drugmakerAlnylam Pharmaceuticals (NASDAQ: ALNY) gained 18.5% last month. The biotech's stock was lifted up by both the insurgent victory of Donald Trump -- presumably because of his less vitriolic stance on U.S. drug pricing schemes than Hillary Clinton -- along with Sanofi's (NYSE: SNY) decision to opt-in to co-develop and co-commercialize the experimental hemophilia treatmentfitusiraninthe United States,Canada, andWestern Europe.
Prior to last month's rally, Alnylam's stock was in a tailspin as a result of its decision to discontinue the development of the late-stagehereditary ATTR amyloidosis drug candidaterevusiran. This experimental drug was expected to generate something along the lines of $1 billion in peak sales, and essentially help to set the stage forAlnylam's transformation into a commercial operation. So it's not surprising that the market frowned upon this key clinical setback.
Alnylam's shareholders are currently waiting on pins and needles for the company's lead product candidatepatisiran's late-stage readout in mid-2017. As a treatment for another form ofhereditary ATTR amyloidosis,patisiran stands to generate peak sales in the neighborhood of $700 million to $800 million, making it a critical asset to keep tabs on moving forward. Apart frompatisiran's forthcoming data readout,Alnylam and Sanofi are also on track to advancefitusiran into a pivotal stage trial in early 2017 based on promising early-stage results.
Continue Reading Below
Image source: Getty Images.
As Alnylam is close to having multiple late-stage candidates under development, once again, and its stock is currently trading at less than four times its last-stated cash position, this clinical-stage biotech is arguably deeply undervalued right now.
Of course, the big concern is that RNA interference therapies, in general, are fraught with safety problems, which is probably why big pharmas have shied away from acquiring companies like Alnylam so far. That said, this niche drug space has produced some stellar results without major safety hang-ups, implying that this fear is, perhaps, overblown. Therefore, investors who are comfortable with elevated levels of risk may want to grab some shares of this RNA interference drugmaker ahead ofpatisiran's pivotal data readout next year.
10 stocks we like better than Alnylam Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alnylam Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.